Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3272068 | Journal de Gynécologie Obstétrique et Biologie de la Reproduction | 2016 | 9 Pages |
Abstract
In France, the prevalence of chronic hepatitis B is about 1% in pregnant women (usually asymptomatic carriers of HBsAg). The risk of maternal-fetal transmission of hepatitis B is particularly high when viral load measured by PCR is higher in mothers (above 7Â log) or HBeAg is present. In case of maternal-fetal transmission of hepatitis B, the risk to the newborn of developing subsequent chronic hepatitis B is very high (90%), with long-term complications such as cirrhosis and hepatocellular carcinoma. The prevention of maternal-fetal transmission is based on systematic testing for hepatitis B during pregnancy, followed by serovaccination of the newborn at birth. If necessary, amniocentesis can be realised but will avoid the realization of a transplacental gesture. In case of high viral load, the establishment of a maternal antiviral treatment with lamivudine or tenofovir from 28Â SA can further reduce the risk of transmission. Given the low resistance it induces, tenofovir should be used preferentially.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
A. Fouquet, A.-C. Jambon, V. Canva, L. Bocket-Mouton, F. Gottrand, D. Subtil,